Actively Recruiting
A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
Led by University of Cincinnati · Updated on 2026-05-04
37
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating whether lattice radiation therapy (LRT) can provide better treatment for large tumors compared to the current standard radiotherapy. This is a Phase II trial conducted at a single institution, focusing on patients with solid tumor malignancies that require radiation treatment. The study also explores how lattice therapy may affect systemic immune responses. Participants will receive lattice radiation therapy consisting of 5 treatment sessions (fractions) delivered every other day. This single-arm trial plans to enroll a total of 37 patients. The primary goal includes evaluating the treatment's effectiveness by measuring tumor response 60 days after treatment and assessing safety through monitoring side effects at multiple time points up to 60 days post-therapy. During the study, participants will undergo assessments at days 5, 15, 30, and 60 after completing therapy to check for any adverse effects. Researchers will also collect data on overall survival up to 12 months post-treatment and gather patient-reported quality of life information at 60 days. Participants will be monitored closely throughout the trial, which emphasizes both treatment outcomes and safety.
CONDITIONS
Brief Title
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Solid tumor malignancy requiring radiation treatment
- Measurable disease present
- Target tumor amenable to lattice therapy planning and immobilization if applicable
- Age 18 years or older
- ECOG Performance status of 2 or less
- Life expectancy greater than 3 months
- Agreement to use birth control or abstinence before and 30 days after treatment if of child-bearing potential
- Ability to understand and willing to sign informed consent
You will not qualify if you...
- Receiving cytotoxic chemotherapy or radiosensitizing agents within 5 days before or after lattice therapy
- Hematologic malignancies like lymphoma or leukemia, or CNS malignancies
- History of conditions that increase radiation toxicity risk
- Known contraindications to radiation therapy
- Uncontrolled intercurrent illness
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 2 weeks
Participants receive lattice radiation therapy consisting of 5 fractions delivered every other day.
5 treatment visits
Duration - Up to 60 days post-treatment
Participants are monitored for safety and response after completing lattice therapy, including assessments at day 5, 15, 30, and 60 post-treatment.
4 follow-up visits
Trial Site Locations
Total: 1 location
1
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45219
Actively Recruiting
Research Team
U
UCCC Clinical Trials Office
A
Andrew Frankart, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here